Skip to main content

Graham Holdings Announces $500M Senior Notes Offering

Tipranks - Thu Nov 13, 2025

Meet Your ETF AI Analyst

Graham Holdings ( (GHC) ) has issued an announcement.

On November 12, 2025, Graham Holdings Company announced a private offering of $500 million in senior unsecured notes due 2033, guaranteed by its domestic subsidiaries. Concurrently, the company plans to amend its revolving credit facility to $400 million, using proceeds to redeem existing notes, refinance loans, and repay term loans, impacting its financial structure and stakeholder interests.

The most recent analyst rating on (GHC) stock is a Buy with a $1163.00 price target. To see the full list of analyst forecasts on Graham Holdings stock, see the GHC Stock Forecast page.

Spark’s Take on GHC Stock

According to Spark, TipRanks’ AI Analyst, GHC is a Outperform.

Graham Holdings scores well due to its strong financial performance and attractive valuation, indicating robust profitability and potential undervaluation. Technical analysis presents mixed signals, with bearish short-term momentum but neutral to positive long-term trends. The absence of earnings call and corporate events data does not impact the overall score.

To see Spark’s full report on GHC stock, click here.

More about Graham Holdings

Graham Holdings Company operates in the media and education industries, providing a range of services including television broadcasting, online and print media, and educational services.

Average Trading Volume: 41,298

Technical Sentiment Signal: Strong Buy

Current Market Cap: $4.8B

For an in-depth examination of GHC stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.